Cargando…
Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats
Infection increases the risk of thrombosis through the activation of inflammation and coagulation. Edoxaban, a direct oral factor Xa inhibitor, is used for the prevention and treatment of thrombotic diseases. The aim of this study was to determine the effects of edoxaban on microvascular thrombus fo...
Autores principales: | Morishima, Yoshiyuki, Shibutani, Tomoko, Noguchi, Kengo, Ito, Yusuke, Honda, Yuko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856452/ https://www.ncbi.nlm.nih.gov/pubmed/33534029 http://dx.doi.org/10.1007/s11239-021-02381-y |
Ejemplares similares
-
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014) -
Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013) -
Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014) -
Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study
por: Ikushima, Ippei, et al.
Publicado: (2020) -
Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response
por: Fang, Lixin, et al.
Publicado: (2022)